ClinicalTrials.gg
RecruitingNCT04441567Updated Oct 7, 2026

Right-Size Clinic Visits Using Memora Platform for PROMIS

An interventional study of Right-size clinic visits in Orthopedic Disorders, sponsored by Boston Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Boston Medical Center · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.
Updated Oct 7, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Developing novel methods of patient communication is crucial in providing value-based care to orthopedic patients. Healthcare technology platforms have been developed to improve patient communication methods particularly for the administration of patient-reported outcome measures (PROMs). However, the majority of these interventions rely on web-based platforms that require patients to have computer access. Among American households earning less than $30,000 per year, only 59% have access to a desktop or laptop and just 47% have broadband internet at home compared to mobile phone penetration which is estimated at 95% of which 93% regularly use text messages. The use of phone messaging may be the most effective means to have patients complete PROMs.

The Patient-Reported Outcomes Measurement Information System (PROMIS) is an NIH-funded, clinically validated method of tracking patient-reported outcomes to efficiently assess patient health status. PROMIS utilizes Item Response Theory (IRT) and computerized adaptive testing (CAT) to improve measurement precision and decrease survey time as compared to traditional PROMs.

The purpose of this two-phase study is to utilize Memora Health's text-messaging platform to collect web-based PROMIS CAT surveys from patients (Phase 1) and use this information to right-size clinic visits (Phase 2).

Read the detailed description

Phase 1 will be a prospective evaluation of patients with the conditions listed. After consent, participants will complete PROMIS CAT questionnaires on their mobile phones to assess health status. During enrollment, participants will choose a method of completing the surveys throughout the duration of the study. The participants will either 1) receive a short message service(SMS) with a secure weblink to complete these PROMIS CAT questionnaires on a secure website, or 2) engage in two-way SMS communication by answering the survey questions individually by texting back their answers. The investigators will explain that the desired method of participation is by weblink due to privacy issues associated with two-way texting. The frequency at which the questionnaires will be sent is condition-specific. All patients will be seen in clinic at standard follow up time-points and will be asked to complete PROMIS questionnaires during each clinic visit, identical to the delivery of surveys while at home. The PROMIS measures collected over a 1-year period will be used to develop patient-based recovery curves.

Phase 2 will begin at the end of Phase 1 and compare each participant's recovery (based on the PROMs) against the established recovery curve that was generated in Phase 1 for their orthopedic condition. The investigators will right-size in-person clinic visits based on individual recovery as compared with expected recovery. Earlier clinic appointments will be given to participants at risk for a poor outcome (defined as any PROMIS score ≥1 standard deviation below the mean). All other participants will receive a phone call to make sure that participants feel they are doing well and to have any issues addressed. If it is felt that a visit is warranted, it will be recommended, and if a subject wishes to have a visit it will be scheduled. If the subject is happy with their progress, then that in-person clinic visit will be deferred until the next standard follow-up visit and the same process will occur. Some in-person visits will be mandatory when a physical exam or x-ray is required for optimal care. These are condition specific. For all participants, a final in-person follow-up visit will occur unless the subject is happy and does not want to be seen in person.

02

Conditions studied

  • Orthopedic Disorders

Keywords

  • PROM
  • PROMIS
  • Memora Health Text messaging platform
  • SMS (Short Message Service)
  • Orthopedic conditions
  • Recovery curves
  • Right-size clinic visits
  • CAT
  • SMS
03

In context

Musculoskeletal Diseases

753 studies on the registry are indexed under Musculoskeletal Diseases; 164 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 76 across 519 interventional studies indexed under Musculoskeletal Diseases.

Browse Musculoskeletal Diseases studies →

Lead sponsor

Boston Medical Center is the lead sponsor of 323 studies on the registry; 33 are open to participants now.

Of its 34 completed or terminated interventional studies of FDA-regulated products, 28 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects that are classified by the Current Procedural Terminology/International Classification of Diseases (CPT/ICD)-10 Diagnosis Codes, having sustained the injury within 3 weeks of enrollment for non-operative treatment or will undergo surgery during the enrollment period:
  • Ankle Fracture
  • Distal Radius Fracture
  • Tibial Plateau Open reduction internal fixation (ORIF)
  • Spine Operative

    • Anterior cervical discectomy with fusion (ACDF)
    • Cervical Laminectomy
    • Lumbar Fusion
    • Lumbar Decompression
  • Spine Non-operative

    • Lumbar Stenosis
    • Lumbar Degenerative Disc Disease
  • Rotator Cuff Repair
  • Anterior cruciate ligament (ACL) Reconstruction
  • Have personal use of cellular phone with access to the internet
  • Speak either English or English as a primary language:

Exclusion criteria

Exclusion Criteria:

  • Limited and non-readers
  • Vulnerable populations - incarcerated patients
  • Patients with no cell phone to use for scoring
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
3,000 participants (estimated)

Study arms

  • No intervention
    Phase 1

    Participants in phase 1 will be observed and data about their recovery time will be collected from which recovery curves will be calculated for Phase 2

  • Experimental
    Phase 2

    Participants in Phase 2 will have their clinic visits potentially revised based on the phase 1 recovery curves which may increase or decrease the number of clinic visits they receive based on the PROMs reported.

    Other: Right-size clinic visits

Interventions

  • OtherRight-size clinic visits

    The curve created in Phase 1 will be used to guide the number of clinic visits based on PROMs reported by the participants in Phase 2.

06

What researchers measure

Primary outcomes

  1. Right-size clinic visits for specific orthopedic conditions

    Right-size clinic visits for patients recovering at/better than expected while maintaining or improving overall patient-reported outcomes (PROMS) will be assessed by comparing to the mean condition-specific recovery curve from phase 1. Earlier clinic visits will be scheduled for those who are more than 1 standard deviation from the mean recovery at any time point and less frequent visits for all others to establish the right size clinic visits.

    Time frame: 2 years

  2. Patient-based recovery curves for specific orthopedic conditions

    Each participant's recovery (based on the patient-reported outcome measures- PROMs) for their orthopedic condition will be assessed against the established recovery curve that was generated in phase one of the research for their condition.

    Time frame: 1 year

Secondary outcomes

  1. Average number of PROMs collected through SMS and weblink

    The number of PROMs collected through SMS and weblink will be assessed. PROMs are standardized, validated questionnaires completed by patients to measure their perception of their functional well-being and health status.

    Time frame: 1 year

  2. Average number of PROMs collected during clinic visits

    The number of PROMs collected during clinic visits will be assessed. PROMs are standardized, validated questionnaires completed by patients to measure their perception of their functional well-being and health status.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Jun 2029, 97 months after the start.

Of 251 non-industry interventional studies with no phase under Musculoskeletal Diseases, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 97 months is above that.

Counting every sponsor, half of 266 studies reached it within 16 months; a quarter within 6 and three quarters within 36.

Musculoskeletal Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Jun 2029, last on Oct 7, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Jun 2029, last on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2020
First posted
Jun 22, 2020
StartActual
May 10, 2021
Primary completionEst.
Jun 2029was Sep 2026
CompletionEst.
Jun 2029was Sep 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Jun 2029
moved 2 times, Oct 1, 2026 – Oct 7, 2026
Study completion
Sep 2026→Jun 2029
moved 2 times, Oct 1, 2026 – Oct 7, 2026
Contact
Study contact changed: K•••@bmc.org · •••5757→K•••@bmc.org · •••5757. See the current contact
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Boston Medical Center · Boston, United StatesContact K•••@bmc.org · •••5757→K•••@bmc.org · •••5757
Oct 1, 2026
Show all 2 updates
  1. Oct 7, 2026
    Primary completion Oct 2026→Jun 2029
    Study completion Oct 2026→Jun 2029
    + 1 other change: verification date
  2. Oct 1, 2026
    Primary completion Sep 2026→Oct 2026
    Study completion Sep 2026→Oct 2026
    Contact Study contact changed: K•••@bmc.org · •••5757→K•••@bmc.org · •••5757. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Boston Medical Center · Boston, United StatesContact K•••@bmc.org · •••5757→K•••@bmc.org · •••5757
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04441567
Responsible party
Sponsor
First posted
Jun 22, 2020
Start date
May 10, 2021
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Paul Tornetta III, MD
Contact
Paul.Tornetta@bmc.org
617 414 5757
Karen McCartney
Contact
Karen.McCartney@bmc.org
617-414-5757
Paul Tornetta III, MD
principal investigator · Boston Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion